A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Latest Information Update: 13 Nov 2019
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 04 Jun 2019 Primary endpoint has not been met (Overall Response Rate) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Results assessing a phase 2 study of tremelimumab plus durvalumab in patients with pleural mesothelioma presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 31 Oct 2018 Status changed from recruiting to suspended due to interim analysis .